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The hallmarks of skin infl  ammation are an in-
fi  ltration of the dermis by monocytes and acti-
vated T cells and an increase in draining lymph 
node cellularity primed by the large-scale im-
migration of dermal DCs via aff  erent lymphat-
ics. These events are coordinated by cytokines, 
including TNF-α and IL-1, that induce matu-
ration and emigration of skin-derived DCs 
(1), leading to exacerbation of infl  ammation 
or eventual fi  brosis through pleiotropic eff  ects 
within aff  ected dermis. To date, much research 
has focused on the mechanisms by which T 
cells are recruited to infl  amed tissues by trans-
migration of blood vessels (for review see 2). 
However, the equally important question of 
how DCs and other leukocytes are recruited 
to lymph nodes by transmigration of lym-
phatic vessels has received far less attention (3). 
Knowledge about the mechanisms for the en-
try of DCs into lymphatics is mostly restricted 
to chemotaxis and the eff  ects of chemokines 
on the process. For example, CC chemokine 
receptor 7 (CCR7), which binds the lymph 
node/lymphatic endothelial–derived CC che-
mokine ligand 21 (CCL21) and CCL19, is 
expressed in mature DCs and mediates their 
traffi   cking from tissue to lymph nodes (4–6). 
Recent evidence indicates the same receptor 
also mediates exit of CD4+ eff  ector memory 
T cells from tissue to lymph (7, 8). Moreover, 
deletion of the gene for CCR7 in knockout 
mice abolishes migration of Langerhans cells 
into dermal lymphatics, whereas the absence 
of lymph node CCL21 (as in the plt mouse, 
paucity of lymph node T cells) suppresses re-
cruitment of DCs to draining lymph nodes and 
subsequent T cell–mediated immunity (9, 10). 
Nonetheless, it remains unclear whether these 
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important lymphatic traffi   cking events are regulated solely by 
chemokines or whether there is an additional requirement 
for adhesion between leukocytes and lymphatic endothelium 
in the process.
In the case of the blood vasculature, it is well documented 
that adhesion and migration across infl  amed vessel endothe-
lium typically involves cytokine-induced expression of key 
leukocyte–endothelial cell adhesion molecules (CAMs)—
  intercellular adhesion molecule 1 (ICAM-1), vascular CAM 
(VCAM-1), and E-selectin (in endothelium)—that promote 
adherence and diapedesis of lymphocytes and monocytes 
through ligation of the counterreceptors αLβ2/αΜβ2 integ-
rin (CD11a/CD18, CD11b/CD18, and LFA-1/Mac I) and 
α4β1 integrin (very late antigen 4) Sialyl LewisX-modifi  ed 
mucoproteins, respectively (for review see 11; 12–14). In 
contrast, cytokine-induced expression of these and other leu-
kocyte–endothelial CAMs on lymphatic vessels has not been 
adequately explored, despite indications that ICAM-1 knock-
out mice have defects in lymph node recruitment of DCs 
(12, 13) and that expression of VCAM-1 in medullary sinus 
coincides with lymphocyte retention in infl  amed  lymph 
nodes (14).
The cellular route by which leukocytes transmigrate lym-
phatic endothelium is equally uncertain. The ultrastructure 
of lymphatic capillaries is distinct from that of small blood 
vessels; most notably, they are not invested with mural cells 
and do not have a conventional basement membrane (3, 15, 
16). Moreover, the initial lymphatics culminate in blind-
ended termini that display occasional interendothelial gaps 
(17, 18) through which plasma and dissolved macromolecules 
are drawn in response to the negative pressure evoked by the 
innate pumping activity of larger lymphatic collectors (19). 
Whether these gaps can also serve as entry points for leuko-
cytes or whether entry involves transmigration at interendo-
thelial tight junctions (paracellular route) or across the 
endothelial cell body (transcellular route) as in the blood vas-
culature (20, 21) is open to conjecture. Likewise, which, if 
any, of these routes contributes to the acceleration in leuko-
cyte transmigration that is triggered by infl  ammation or how 
accelerated entry might be regulated is unclear. In the few 
cases where transmigration has been observed in detail (e.g., 
the entry of DCs to lymph vessels in infl  amed mouse skin 
explants), leukocytes were seen to undergo massive shape 
changes during passage into the vessel lumen (22, 23). Thus, 
whatever the route of entry, it is likely that intimate contacts 
form between leukocytes and infl  amed lymphatic endothe-
lium that could well regulate cell transit.
We have focused on the molecular mechanisms of lym-
phatic transmigration in the belief that an understanding of 
the process is important not only from the standpoint of 
fundamental biology but also for the development of more 
eff  ective therapies to block infl  ammation and enhance vac-
cine delivery. We have found that lymphatic endothelium 
undergoes a program of activation during infl  ammation to 
support increased leukocyte transmigration in which the 
adhesion molecules ICAM-1 and VCAM-1 play key roles. 
Figure 1.  Characteristics of primary HDLECs isolated by LYVE-1 
immunoselection. HDLECs isolated from human dermis by LYVE-1 
immunomagnetic bead selection are shown after dual immunofl  uore-
scence staining for lymphatic and blood vascular-specific markers. 
(A and B) Confl  uent monolayers stained for the panendothelial marker 
CD31 and the lymphatic endothelial markers podoplanin or LYVE-1, 
  respectively. In contrast to podoplanin, which is expressed by all HDLECs, 
LYVE-1 shows considerable variation, refl  ecting the heterogeneity seen in 
normal tissue lymphatics (see Results). (C) Triple staining for CD31, the 
lymphatic endothelial transcription factor PROX-1, and the nuclear stain 
DAPI. Note that all cells contain PROX-1–positive nuclei. (D) HDLEC mono-
layers stained for podoplanin and the blood vascular marker pal-E. Note 
the complete absence of pal-E–positive cells. Blood vascular endothelial 
cells positive for pal-E in the mixed endothelial culture preceding LYVE-1 
immunoselection are shown for comparison (inset). (E) FACS histograms 
of HDLECs stained for CD31, podoplanin, or LYVE-1 (red). Isotype-matched 
controls are shown (black).JEM VOL. 203, November 27, 2006  2765
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These important fi  ndings reveal a functional similarity be-
tween two otherwise distinct vasculatures and point to a 
much more active role for the lymphatics in infl  ammation 
than previously anticipated.
RESULTS
Cytokine-induced expression of key leukocyte adhesion 
molecules and chemokines in primary human dermal 
lymphatic endothelial cells (HDLECs)
To generate cells for analysis of the infl  ammatory response 
and its eff  ects on DC transmigration, we isolated primary 
HDLECs from the dermis of freshly resected breast tissue or 
abdominoplasty by enzymatic digestion and magnetic bead 
immunoselection using antibody to lymph vessel endothelial 
hyaluronan receptor 1 (LYVE-1), a molecule whose pref-
erential expression in lymphatic endothelium has been well 
documented (see Materials and methods) (24–26). The re-
sulting cells comprised at least 99% LECs, as assessed by im-
munostaining for the sialomucin marker podoplanin (27) and 
the lymphatic lineage-associated transcription factor Prox-1 
(28, 29), either alone or in combination with the panen-
dothelial marker CD31 (Fig. 1, A, C, and E) (30). Parallel 
immunostaining for LYVE-1 (both alone and in combina-
tion with CD31) showed that the majority of the population 
was positive for the receptor even though there was clear 
heterogeneity in the level of expression among individual 
LECs (Fig. 1, B and E). This is in line with the observations 
of other researchers that indicate the receptor is expressed 
to variable extents in individual lymphatic vessels (19, 31) 
and primary LEC lines (32, 33, 34, 35), as well as with our 
own fi  ndings that LYVE-1 can be specifi  cally downmod-
ulated in cultured LECs, e.g., after exposure to cytokines 
Figure 2.  Infl  ammatory cytokines up-regulate surface expression 
of ICAM-1, VCAM-1, and E-selectin in cultured HDLECs. Cells were 
cultured for 24 h in the presence of individual proinfl  ammatory cytokines 
or chemokines before immunostaining for either (A) VCAM-1 or (B) ICAM-1 
and quantitation by FACS analysis. Data represent the mean ± SEM 
(n = 3). (C and D) Dot plots show VCAM-1 or ICAM-1 expression in HDLECs 
cultured in the presence or absence (control) of TNF-α and assessed by 
dual staining for podoplanin and CAMs. Note that all cells expressing 
CAMs are positive for podoplanin (top right quadrants). (E) Representative 
double immunofl  uorescence micrographs showing induction of CAMs and 
E-selectin (green) in podoplanin-positive (red) HDLECs, as indicated with 
nuclei counterstained for DAPI. Bar, 50 μm.2766  TRANSMIGRATION MECHANISMS IN INFLAMED LYMPHATIC ENDOTHELIUM | Johnson et al.
(Fig. S1 E, available at http://www.jem.org/cgi/content/
full/jem.20051759/DC1; see Fig. S3 B; and not depicted). 
Importantly, no cells expressing the blood vascular endo-
thelial-specifi  c, vesicle-associated pal-E antigen (36, 37) 
were detected in our LEC cultures, these having been effi   -
ciently depleted in two successive rounds of LYVE-1 immuno-
selection (Fig. 1 D).
We next investigated the eff  ects of infl  ammatory cyto-
kines, focusing in particular on the leukocyte adhesion mole-
cules ICAM-1, VCAM-1, and E-selectin, whose surface 
expression is known to be induced on activated blood vascu-
lar endothelium (38–40). As shown by FACS analysis and 
immunofl  uorescence microscopy (Fig. 2, A–E), a minor pro-
portion of resting HDLECs expressed low levels of ICAM-1, 
whereas VCAM-1 and E-selectin were virtually absent. 
However, treatment with the cytokine TNF-α led to a dra-
matic up-regulation in surface expression (40–80-fold) of all 
three CAMs. These eff  ects of TNF-α were both potent 
  (requiring levels below 1 ng/ml for half-maximal induction; 
Fig. S1) and rapid (T1/2 of 6–12 h for ICAM-1 and VCAM-1; 
T1/2 of  4 h for E-selectin; Fig. 3, A–C). The characteristics 
of the response, its magnitude, and the transient nature of 
E-selectin expression (Fig. 3 C) were rather similar to those 
previously described for blood vascular endothelium (i.e., the 
human umbilical vein epithelial cell line; references 41, 42). 
Moreover, the induction of CAM expression by TNF-α ap-
peared to be independent of mitogenesis or apoptosis within 
the range used in our experiments, involved no loss of 
cell integrity, and was completely reversible within 24 h of 
cytokine withdrawal (Fig. S2, A–C, available at http://www.
jem.org/cgi/content/full/jem.20051759/DC1). Among other 
cytokines, TNF-β (lymphotoxin-α), IL-1α, and to a  marginal 
extent IFN-γ also induced expression of ICAM-1, whereas 
IL-2, IL-6, IL-8, and the infl  ammatory chemokine macrophage 
infl  ammatory protein 3α (MIP-3α; CCL20) had no such 
  eff  ect (Fig. 2, A and B).
As induction of CAMs had not been reported previously 
in LECs, we considered the possibility that the CAM-positive 
cells in our experiments represented a subpopulation of con-
taminating blood vascular endothelial cells. However, two-
color fl  ow cytometry and immunofl  uorescence microscopy 
(Fig. 2, C–E) clearly demonstrated that all VCAM-1– and 
Figure 3.  Kinetics of TNF-induced CAM and E-selectin expression 
in cultured primary HDLECs. (A–C) Respective time courses for induc-
tion of VCAM-1, ICAM-1, and E-selectin in HDLECs cultured for 0–48 h in 
the presence or absence of 1 ng/ml TNF-α, as assessed by FACS analysis. 
Representative histograms are shown for cells stained with isotype-
matched control Ig (light gray) or mAbs to the appropriate adhesion mol-
ecules in unstimulated cells (black) or cells treated with TNF-α for 3 h 
(dark gray), 6 h (blue), 12 h (green), and 24 h (red).JEM VOL. 203, November 27, 2006  2767
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ICAM-1–expressing cells were positive for podoplanin, thus 
confi  rming their identity as LECs. Moreover, we consistently 
observed induction of CAMs in a total of fi  ve independent cell 
preparations isolated by the LYVE-1 immunoselection proce-
dure, in addition to preparations of HDLECs immunoisolated 
by either CD34/podoplanin selection (43) or outgrowth from 
commercial human dermal microvascular cell cultures (35) 
and in mouse dermal LECs (MDLECs) immunoisolated by 
LYVE-1 selection (Fig. S3, available at http://www.jem.
org/cgi/content/full/jem.20051759/DC1; and not depicted). 
Thus, we are confi  dent that the capacity to express leukocyte 
CAMs is a genuine property of the bulk HDLEC population 
rather than the result of contamination with biliary epithelial 
cells or a subpopulation undergoing dediff  erentiation.
Finally, we investigated the eff  ects of TNF-α on the pro-
duction of leukocyte chemokines using appropriate ELISAs. 
The results (Fig. 4) show that resting, unstimulated HDLEC 
cultures secrete only trace levels of the major T cell and 
monocyte chemokines regulated on activation, normal T cell 
expressed and secreted (RANTES; CCL5), monocyte che-
moattractant protein 1 (MCP-1; CCL2), and (MIP-3α; 
CCL20), confi  rming and extending upon previous fi  ndings 
(43). Importantly, however, stimulation with TNF-α trig-
gered a considerable (>100-fold) rise in secretion of all three 
chemokines over a period of 24–48 h, reaching fi  nal levels of 
7–55 ng/ml (Fig. 4). In contrast, secretion of both Epstein-
Barr virus–induced molecule 1 ligand chemokine (CCL19) 
and secondary lymphoid tissue (CCL21)—chemokines asso-
ciated with lymph node traffi   cking (4)—was below detect-
able levels (80 and 15 pg/ml, respectively; unpublished data) 
and was evidently not induced by treatment of LECs with 
infl  ammatory cytokines.
Extent of the infl  ammatory cytokine–induced expression 
program in LECs revealed by microarray analysis
To defi  ne infl  ammation-induced changes in HDLEC gene 
expression more comprehensively, we examined the RNA 
profi  les of control and TNF-α–treated cells by gene chip ar-
ray analysis using Aff  ymetrix human U-133 arrays. The re-
sults (summarized in Table I and completely presented in 
Table S1, available at http://www.jem.org/cgi/content/full/
jem.20051759/DC1) revealed a total of 424 genes that were 
up-regulated and 171 that were down-regulated by a factor 
of twofold or greater (P ≤ 0.1). Notably, VCAM-1 (214-
fold), ICAM-1 (7.7-fold), and E-selectin (160-fold) were all 
highly up-regulated, as were the levels of the leukocyte che-
mokines MCP-1, RANTES, and MIP-3α, confi  rming our 
fi  ndings at the protein level using FACS analysis and ELISA 
(see previous section). Moreover, RNA levels were also 
up-regulated for the neutrophil chemoattractants epithelial 
neutrophil activator 78 (ENA-78; CXC chemokine ligand 5 
[CXCL5]) and growth-regulated oncogene β (GROβ; 
CXCL2), the monocyte/macrophage chemokines fractalkine 
(CX3CL1) and CSF-1, and CCR10, a receptor for the 
  chemokine CCL27 (cutaneous T cell–attracting chemokine) 
Figure 4.  TNF-𝗂 induces proinfl  ammatory chemokine production 
in cultured primary HDLECs. Cells were stimulated with 1 ng/ml TNF-α 
over a time course of 48 h, and concentrations of MCP-1, RANTES, and 
MIP-3α secreted into the culture supernatant were measured by ELISA. 
Data represent the mean ± SEM (n = 3).
Table I. Up-regulation of representative genes
Transcript Fold change
(P < 0.05)
VCAM-1 214 
ICAM-1 7.7
E-selectin 160
Claudin-1 6.7
MIP-3α (CCL20) 444
ENA-78 (CXCL5) 388
RANTES (CCL5) 48
GROβ (CXCL2) 38
Fractalkine (CX3CL1) 18.3
IL-6 18
MCP-1 (CCL2)* 7
IL-32* 5.8
CSF-1 3.7
CCR10 7
IL-12R* 2.4
Toll-like receptor 2 26
Toll-like receptor 1 3.1
MMP19 3.6
ADAMTS3 7.4
TNFSF9 (CD137) 35
TNFSF3 (LT-β)2 3
Representative genes were up-regulated more than twofold by TNF-α stimulation 
of primary HDLECs at P < 0.05 (or P < 0.1, as indicated by *).2768  TRANSMIGRATION MECHANISMS IN INFLAMED LYMPHATIC ENDOTHELIUM | Johnson et al.
produced by infl  amed epidermal keratinocytes (44), indicat-
ing a broad chemoattractant response within infl  amed lym-
phatic endothelium. Interestingly, the array data also showed 
signifi  cant up-regulation of Toll-like receptor 2, the tight 
junctional component claudin-1, and the metalloproteinases 
MMP19 and ADAMTS3 (Table I). However, there was 
no change in abundance of transcripts for either CCL21 or 
CCL19, both of which are implicated in the exit of DCs 
from tissues to aff  erent lymphatics and traffi   cking to lymph 
nodes (9, 10).
Comparable changes in the transcriptional profi  le  of 
MDLECs were induced by treatment with TNF-α, as revealed 
in microarray analyses using the Aff  ymetrix mouse 430 array 
(Table S2, available at http://www.jem.org/cgi/content/
full/jem.20051759/DC1), indicating the broad similarity in 
LEC response to infl  ammation between species.
In vivo evidence of a functional role for VCAM-1 and 
ICAM-1 in infl  ammation-induced lymphatic transmigration
Having established infl  ammation-induced expression of leu-
kocyte CAMs in primary LECs in vitro, we next asked 
whether a similar response occurs during infl  ammation in 
vivo, using the well-characterized oxazolone-induced skin 
contact hypersensitivity model in BALB/c mice (45, 46). To 
achieve this, we prepared sections of dermis from infl  amed 
and contralateral uninfl  amed ears (see Materials and methods) 
at various time points after oxazolone challenge and immuno-
stained for CAMs in both whole-mount and thin sections. 
The results (Fig. 5, A and B) show that VCAM-1 and ICAM-1 
are indeed expressed on infl  amed lymphatic vessels—distin-
guished by their expression of podoplanin and comparatively 
large vessel diameters—in addition to small blood capillaries, 
whereas both CAMs were absent from the lymphatics of un-
challenged tissue. Interestingly, expression in infl  amed lym-
phatics was more focal than in infl  amed blood vessels (Fig. 5, 
A and B; and not depicted), possibly indicative of diff  erent 
kinetics of induction within the two vasculatures. Neverthe-
less, quantitative estimates revealed that  50% of podo-
planin-positive lymphatics stained for ICAM-1 and 60% for 
VCAM-1 within 18–24 h of allergen administration (Fig. 5, 
C and D). Similar levels of CAM expression were also seen 
among podoplanin-positive lymphatics (60% ICAM-1+ ves-
sels vs. 70% VCAM-1+ vessels) 24 h after direct stimulation 
with TNF-α when ex vivo mouse skin explants were incu-
bated with the cytokine (unpublished data). Moreover, visu-
alization of APCs in the dermis of oxazolone-treated mice by 
immunostaining for MHC class II, ICAM-1, and podoplanin 
revealed many such cells in close association with CAM-pos-
itive lymphatic vessels (Fig. S4, available at http://www.jem.
org/cgi/content/full/jem.20051759/DC1), suggesting but 
not proving that ICAM-1 might indeed play a role in lym-
phatic transmigration in an infl  ammatory context. The diam-
eter of these superfi  cial vessels (average  50 μm) is also 
consistent with their identity as initial lymphatics rather than 
the larger smooth muscle–invested lymphatic collectors 
(100–200 μm) that are found in the deeper dermis.
Figure 5.  In vivo expression of ICAM-1 and VCAM-1 in mouse 
dermal lymphatics induced by skin contact hypersensitivity. Skin 
infl  ammation was induced in mouse ear by sensitization and subsequent 
challenge with oxazolone before analysis of lymphatic vessel CAM ex-
pression by immunofl  uorescence microscopy. (A and B) Whole-mount 
sections of oxazolone-challenged and contralateral-unchallenged 
(control) ears dual-stained for podoplanin (green) and ICAM-1 or VCAM-1, 
respectively (red). Note the weak expression of ICAM-1 confined to 
  podoplanin-negative (blood) vessels in uninfl  amed skin (A) and the focal 
up-regulation of both ICAM-1 and VCAM-1 on podoplanin-positive 
(lymphatic) vessels in infl  amed skin (A and B). Images were captured by 
confocal microscopy. Bars, 100 μm. (C and D) Quantitative estimates for 
the numbers of ICAM-1+/podoplanin+ and VCAM-1+/podoplanin+ ves-
sels determined by counting 21 separate fi  elds of view (7 fi  elds/mouse) 
in control and oxazolone-treated ear sections. Data represent the mean 
± SEM.JEM VOL. 203, November 27, 2006  2769
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To assess the functional role of CAMs in lymphatic trans-
migration in vivo, we imposed blockade by the injection 
of oxazolone-treated mice with neutralizing antibodies to 
ICAM-1 (mAb YN1/1.7.4 [47]) or VCAM-1 (mAb 6C7.1 
[48]) and tracked migration of cutaneous DCs to lymph 
nodes detected by FITC skin painting. The results of these 
experiments (Fig. 6 A) show that blocking antibodies to ei-
ther VCAM-1 or ICAM-1 consistently suppressed lymph 
node traffi   cking  of  FITC+/CD11c+ by >60% compared 
with isotype-matched Ig controls. Given that cutaneous DCs 
migrate to lymph nodes almost exclusively via aff  erent lym-
phatics rather than entering the blood circulation (49), these 
fi  ndings argue for a role of ICAM-1 and VCAM-1 in either 
proximal vessel entry, migration, or egress from the drain-
ing lymph node. To further distinguish between these pos-
sibilities, we traced the fate of emigrating DCs during CAM 
adhesion blockade in a separate set of experiments in which 
we adoptively transferred mature 5-chloromethylfl  uorescein 
diacetate (CMFDA)–labeled bone marrow–derived DCs into 
the dermis of oxazolone-treated mice. As shown in Fig. 6 B, 
virtually all CMFDA-labeled DCs had already exited the 
dermis by 24 h after adoptive transfer in mice treated with 
isotype-matched control Ig and few, if any, were detected 
in the vicinity of lymphatics. In contrast, large numbers 
of CMFDA-labeled DCs could be seen in the dermis of 
ICAM-1 mAb YN1-1–treated mice, and these were  associated 
Figure 6.  In vivo traffi  cking of skin DCs via afferent lymphatics is 
dependent on ICAM-1 and VCAM-1 adhesion. The involvement of 
ICAM-1 and VCAM-1 in the traffi  cking of DCs via afferent lymphatics 
was investigated in mice with oxazolone-induced skin hypersensitivity. 
(A) Recoveries of FITC+/CD11c+ skin DCs in the draining lymph nodes 24 h 
after FITC skin painting of oxazolone-sensitized mice that received prior 
injection of neutralizing mAbs to VCAM-1, ICAM-1, or control rat Ig. Data 
represent the mean recoveries ± SEM (obtained from three separate 
  experiments). (B) To show retention of DCs within the skin, CMFDA-labeled 
bone marrow–derived DCs from a littermate were intradermally injected 
into the ear tissue of sensitized mice that received prior injection of a 
neutralizing mAb to ICAM-1 (YN1-1) or control rat Ig. After 24 h, ears 
were removed, and whole-mount staining was performed using anti-
podoplanin with Alexa Fluor 568 (red) and Cy5-conjugated goat anti–rat 
Cy5 (blue) to detect binding of neutralizing antibody within the tissue. 
Bars, 100 μm.2770  TRANSMIGRATION MECHANISMS IN INFLAMED LYMPHATIC ENDOTHELIUM | Johnson et al.
with podoplanin-positive initial lymphatics that could be 
seen to express high levels of ICAM-1 through YN1-1 stain-
ing (Fig. 6 B, bottom). There was no obvious association 
of DCs with ICAM-1-positive blood vessels. Although the 
ICAM-1 molecule is expressed at low levels by mature DCs 
themselves, this was previously shown not to be required 
for traffi     cking to lymph nodes (13). Hence, our results 
provide new evidence that CAMs expressed on lymphatic 
  endothelium are required for effi   cient DC transmigration of 
infl  amed lymphatics.
Analysis of the molecular mechanisms for ICAM-1– 
and VCAM-1–mediated translymphatic migration
Finally, we investigated the mechanistic basis for CAM-me-
diated lymphatic transmigration using a quantitative in vitro 
assay that measured the passage of in vitro LPS- stimulated 
CD14+ human blood monocyte-derived DCs (MDDCs) across 
monolayers of primary HDLECs in Boyden chambers. The 
mature promigratory phenotype of these DCs (CD80+, CD83+, 
CD86+, and MHC class IIhigh) is shown in Fig. S5 (available 
at http://www.jem.org/cgi/content/full/jem.20051759/DC1). 
Figure 7.  MDDC transmigration of TNF-α–stimulated HDLEC 
monolayers is dependent on ICAM-1 and VCAM-1. Transmigration 
of Cell Tracker Green fl  uorescently labeled MDDCs across either unstimu-
lated or TNF-α–stimulated HDLEC monolayers plated on the undersurface 
of Fluoroblok fi  lters was monitored in the presence or absence of selected 
adhesion blocking antibodies over a 12-h period. Progress curves are 
shown for MDDC transmigration across (A) control unstimulated versus 
TNF-α–stimulated HDLECs, (B) TNF-α–stimulated HDLECs treated with 
control rat IgG versus VCAM-1–neutralizing mAb P8B1, and (C) TNF-α–
stimulated HDLECs treated with control rat IgG versus ICAM-1–
neutralizing mAb P2A4. Data represent the mean ± SEM (n = 4). 
(D) Comparative effects of individual ICAM-1 mAbs 15.2 and P2A4, 
VCAM-1 mAbs 51-10C9 and P8B1, ICAM-1 mAb 15.2 and VCAM-1 mAb 
P8B1 together, the LFA-1 mAb 24, and control mouse IgG on MDDC 
transmigration of TNF-α–stimulated HDLECs. The level of transmigration 
across unstimulated HDLECs is shown for comparison. Data from three 
independent experiments are normalized to the measured levels of trans-
migration in the presence of control IgG (100% maximal transmigration) 
in each case and represent the mean ± SEM (n = 4). (E) Permeability of 
confl  uent HDLEC monolayers to unconjugated Alexa Fluor 488 measured 
as dye recovered in the lower chamber of Fluoroblok fi  lter wells after a 6-h 
incubation at 37°C. Data represent the mean ± SEM.JEM VOL. 203, November 27, 2006  2771
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To mimic the tissue exit of DCs via initial lymphatics in vivo 
(i.e., basolateral to luminal migration), we plated HDLECs 
on the lower side of UV-opaque Fluoroblok fi  lters and 
monitored transit of CMFDA (Cell Tracker Green)-labeled 
MDDCs from the upper to the lower compartment. The result-
ing monolayers showed some permeability to a small-molecule 
probe (fl  uorescent-labeled goat IgG; see Materials and methods) 
even when fully confl  uent (Fig. 7, E and F; and Fig. S6), 
perhaps refl  ecting some retention of the native overlapping 
junction architecture. As shown by the time course in Fig. 
7 A, LPS-matured DCs displayed substantial migration across 
resting unstimulated HDLECs ( 10% of input cells trans-
migrated after 8 h). However, earlier stimulation of HDLEC 
monolayers with 1 ng/ml TNF-α for 24 h led to a substan-
tial increase in the rate and extent of MDDC transmigration 
after a lag period of  3 h (range = 1–3 h) after MDDC 
Figure 8.  VCAM-1 and ICAM-1 are expressed on both luminal 
and basolateral surfaces of HDLECs. Cells were cultured on clear-
membrane inserts and stimulated with TNF-α for 24 h before staining 
with antipodoplanin (red) and either anti–ICAM-1 or anti–VCAM-1 (blue) 
and analysis by confocal microscopy. Staining was performed either on 
HDLECs cultured (A) in the absence of MDDCs or (B) at 10 h after addition 
of Cell Tracker Green fl  uorescently labeled MDDCs. (A, top) Asterisks de-
pict the axis through which individual LECs were imaged in z-section 
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addition (Fig. 7 A). This TNF-α–induced component of 
transmigration was not caused by a simple increase in mono-
layer permeability because it was blocked in dose-dependent 
fashion by the addition of neutralizing antibodies specifi  c 
to either ICAM-1 (mAbs P2A4 or 15.2) or VCAM-1 (mAb 
51-10C9), added either singly or in combination (Fig. 7, B–D; 
and Fig. S7). No such inhibition was seen with unstimulated 
LECs (unpublished data). In addition to these CAM-blocking 
mAbs, considerable inhibition of transmigration was also 
  observed after the addition of the β2 integrin–neutralizing 
antibody mAb 24, consistent with a role for this integrin as 
an LEC CAM counterreceptor on DCs (Fig. 7 D). However, 
in the case of the ICAM-1 mAbs, inhibition of transmigra-
tion could be assigned to the blockade of antigen on LECs 
rather than DCs (which express lower but substantial levels of 
ICAM-1; Fig. S5) because preincubation with the latter had 
no eff  ect (not depicted).
Interestingly, MDDCs were also found to transmigrate 
TNF-α–activated LECs in the luminal to basolateral direc-
tion (assessed by plating LECs on the upper surface of fi  lters) 
with a similar time course and CAM dependence to basolateral-
luminal transmigration (Fig. S8, available at http://www.jem.
org/cgi/content/full/jem.20051759/DC1; and not depicted). 
To determine whether these properties are refl  ected in the 
polarity of CAM distribution in TNF-activated LECs, we 
performed dual fl   uorescence staining of monolayers for 
ICAM/VCAM and podoplanin and analyzed the resulting 
sections by confocal microscopy. As shown in Fig. 8, both 
ICAM-1 and VCAM-1 could be seen on the apical as well 
as the basolateral face of the endothelial plasma membrane, 
indicating no obvious polarity in distribution. Moreover, 
ICAM-1 appeared to be distributed in a ring beneath indi-
vidual MDDCs contacting the LEC monolayer as visualized 
by CMFDA labeling (Fig. 8 A), whereas VCAM-1 showed a 
more patchy distribution (Fig. 8 B).
The clearest interpretation of our fi  ndings is that ICAM-1 
and VCAM-1 in LECs mediate a leukocyte adhesion step 
that is prerequisite for activation-induced transmigration, 
analogous to the CAM-mediated fi  rm adhesion that precedes 
leukocyte diapedesis in blood vascular endothelium. To ex-
plore this issue further, we measured adhesion of CMFDA-
labeled MDDCs to TNF-activated HDLECs cultured in 
24-well plates. As shown in Fig. 9, MDDCs displayed con-
siderable binding to activated LECs within 3 h of incubation, 
increasing twofold after 10 h in a time course that resembled 
MDDC transmigration (Fig. 7). Moreover, when the eff  ects 
of antibody blockade were examined (ICAM-1 mAbs P2A4 
and 15.2 and VCAM-1 mAbs Ig11 and P8B1), it was clear 
that only binding at the later (10 h) and not the earlier (3 h) 
time point was reduced (Fig. 9). Binding during this early lag 
period is therefore CAM-independent and may represent a 
period during which chemokine-induced activation of DC 
integrins occurs.
In summary, we conclude that MDDC transmigration of 
activated LECs in vitro involves an initial CAM-independent 
interaction between the two cell types that is followed by sec-
ondary ICAM/VCAM-mediated adhesion and transmigration.
D  I  S  C  U  S  S  I  O  N 
The mechanisms by which leukocytes exit the tissues via 
lymph and migrate to draining lymph nodes have remained 
unclear despite their central importance for effi   cient genera-
tion of the immune response. The aff  erent lymphatics must 
cater for both low-level traffi     cking of APCs during nor-
mal immune surveillance and the increase in DC, eff  ector 
memory T cell, and neutrophil traffi   cking that is triggered 
by tissue infl  ammation (for review see reference 3). In this 
manuscript, we set out to defi  ne the mechanisms underly-
ing these processes using a combination of in vitro studies 
with primary dermal LECs and in vivo studies with a mouse 
model of oxazolone-induced skin infl  ammation. Specifi  cally, 
we showed that cultured primary HDLECs and MDLECs 
respond to the cytokines TNF-α and TNF-β (lymphotoxin-α), 
and to a lesser extent IL-1, by rapidly and reversibly up-
regulating expression of the leukocyte adhesion molecules 
ICAM-1, VCAM-1, and E-selectin, together with synthesis 
and release of chemotactic agents, including the key infl  am-
matory CC chemokines CCL5 (RANTES), CCL2 (MCP-
1/JE), and CCL20 (MIP-3α). In addition, we demonstrated 
the induction of ICAM-1 and VCAM-1 expression in aff  er-
ent lymphatic vessels draining the skin of oxazolone-treated 
mice in vivo and presented evidence that administration of 
Figure 9.  MDDC adhesion to TNF-α–stimulated HDLECs is de-
pendent on ICAM-1 and VCAM-1. Cell Tracker Green fl  uorescently 
labeled MDDCs were applied to TNF-α–stimulated HDLEC monolayers 
plated in 24-well plates, preincubated with either IgG control or ICAM-1 
mAbs (15.2 or P2A4) or VCAM-1 mAbs (P8B1 or IGII), in triplicate. At 3 and 
10 h, the numbers of adherent MDDCs were measured. Representative 
data from three independent experiments are shown and represent 
the mean ± SEM (n = 3).JEM VOL. 203, November 27, 2006  2773
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ICAM-1– and VCAM-1–neutralizing antibodies blocked 
exit of CD11c-positive skin DCs via aff  erent  lymphatics. 
  Finally, we presented evidence from in vitro lymphatic trans-
migration assays with MDDCs that ICAM-1 and VCAM-1 
mediate infl  ammation-induced transmigration by promoting 
leukocyte-endothelial adhesion.
The induction of CAM expression in activated lymphatic 
vessel endothelium reveals an unexpected similarity with the 
blood vasculature, where up-regulation of these same molecules 
in infl  amed postcapillary venules promotes leukocyte transmi-
gration by mediating fi  rm adhesion (for review see reference 2). 
In hemovascular transmigration, ICAM-1 and VCAM-1 pro-
mote stable adhesion of leukocytes to the apical endothelial 
membrane surface after their initial capture from blood fl  ow and 
tethering on E- and P-selectin (50). Binding via ICAM-1 and 
VCAM-1 then allows the adherent leukocytes to crawl toward 
intercellular junctions (51), where additional interactions with 
the homophilic adhesion molecules CD31 (platelet/endothelial 
cell adhesion molecule 1) and CD99, together with junctional 
molecules such as junctional adhesion molecule 1 (JAM-1) 
and VE-cadherin, promote diapedesis (52–54). The predic-
tion from our own experiments that ICAM-1 and VCAM-1 
would mediate lymphatic vascular transmigration through a 
similar mechanism of leukocyte adhesion was confi  rmed by 
our fi  nding that LPS-treated MDDCs bind to TNF-activated 
LECs in static assays and that the interaction was blocked by 
CAM-neutralizing mAbs using similar concentrations to those 
that blocked transmigration. There is also the likelihood that 
events downstream of this CAM-mediated adhesion might be 
similar to those in the hemovasculature, given that primary 
HDLECs express similar junctional molecules, including VE-
cadherin and JAMs, and that LEC monolayers can form both 
tight and adherens junctions in vitro (43). Furthermore, mice 
with targeted deletion of the gene for JAM-1 (JAM-A) dis-
play abnormalities in DC traffi   cking to lymph nodes, consistent 
with a role for the molecule in lymphatic vessel diapedesis (55). 
Detailed functional studies of these molecules in lymphatics are 
therefore clearly warranted.
A key question regarding entry of leukocytes to the aff  er-
ent lymphatics is whether transmigration occurs at the dis-
tinctive overlapping junctions found within some initial 
lymphatics, at conventional interendothelial junctions, or 
through the endothelial cell body. It is interesting to note 
that docking structures containing ICAM-1 and VCAM-1 
that were shown to mediate leukocyte transcellular/paracel-
lular migration in hemovascular endothelial cells have also 
been observed in cells resembling a lymphatic phenotype 
(56). Hence, it may be that leukocytes can transmigrate lym-
phatic endothelium using more than one mechanism, and it 
will be of major interest to determine the preferred route for 
individual leukocyte populations and the factors infl  uencing 
such choice in future experiments.
It is generally assumed that most leukocyte traffi   c through 
aff  erent lymphatics involves transmigration in the basolateral 
to luminal direction. Nevertheless, it is also possible that re-
verse migration in a luminal to basolateral direction might 
occur. Such a notion is supported by our fi  nding that ICAM-1 
and VCAM-1 are expressed on both the upper and lower 
faces of the endothelial membrane in primary HDLECs in 
vitro and that activated HDLECs promote CAM-dependent 
migration of MDDCs equally in both directions. If this phe-
nomenon occurs in vivo, it raises the intriguing possibility 
that some leukocytes might exit the aff  erent lymphatics and 
reenter at diff  erent points within infl  amed tissue, a process 
that might increase the effi   ciency of immune surveillance. 
Bidirectional migration across activated lymphatic sinus en-
dothelium could also be envisaged to play roles in traffi   cking 
within infl  amed lymph nodes.
Finally, besides identifying mechanisms by which adhe-
sion molecules facilitate transmigration of activated lym-
phatics, we also identifi  ed several chemokines that could 
potentially direct the process. Although existing evidence 
indicates that the major chemokine for directing lymphatic 
entry of mature DC and memory T cell entry is CCL21 
(also known as secondary lymphoid chemokine, or slc), 
which binds the G protein–coupled receptor CCR7 (5, 9, 
10), it seemed likely to us that other chemoattractants might 
also be involved. As indicated by the results of gene chip 
microarray analyses and chemokine ELISAs presented in this 
manuscript, it is now clear that activated HDLECs synthe-
size a large number of diff  erent chemoattractants, including 
the T cell/monocyte chemokines CCL20 (MIP-3α), CCL5 
(RANTES), CCL2 (MCP-1), and CX3CL1 (fractalkine). 
Release of these chemokines in vivo might be envisaged to 
promote lymph node traffi   cking of those newly extravasated 
monocytes and immature DCs bearing cognate CCR2, 
CCR5, CCR6, and CX3CR that enter skin and other 
  tissues in response to infl  ammation and that subsequently 
mature into professional APCs (57, 58). Moreover, secretion 
into lymph could have long-range eff  ects on cell traffi   cking 
in the blood vasculature (59). Thus, “activated” LECs may 
well be the source of CCL2 (MCP-1) in infl  amed skin that 
was shown recently to be rapidly transported via aff  erent 
lymph to the luminal surface of draining lymph node high 
endothelial venues, where it triggered integrin-mediated 
  arrest and recruitment of monocytes from the blood cir-
culation (60). Overall, the broad range of chemoattractants 
that we observed in cytokine-stimulated LECs, including 
both monocyte/T cell chemokines and neutrophil chemo-
kines such as CXCL2 (GROβ) and CXCL5 (ENA-78), 
suggests a far greater role for lymphatics in coordinating 
infl  ammatory leukocyte recruitment than has previously 
been appreciated.
In conclusion, we have shown for the fi  rst time that in-
fl  amed lymphatic endothelium promotes the exit of leuko-
cytes from tissue to aff  erent lymph through newly induced 
expression of the adhesion molecules ICAM-1 and VCAM-1, 
which were previously thought to be specifi  c for blood vessel 
transmigration. These fi  ndings reveal an overlap between the 
traffi   c signals within the blood and lymphatic circulations and 
identify the process of lymphatic transmigration as a potential 
target for antiinfl  ammatory drug therapy.2774  TRANSMIGRATION MECHANISMS IN INFLAMED LYMPHATIC ENDOTHELIUM | Johnson et al.
MATERIALS AND METHODS
Human and animal studies. All studies using human tissue were approved 
by the Oxford Regional Ethics Committee. All animal studies were per-
formed under the appropriate Home Offi   ce licenses and institute guidelines.
Isolation of primary HDLECs and MDLECs. HDLECs were prepared 
from healthy adults undergoing elective surgery (breast reduction and ab-
dominoplasty). MDLECs were prepared from the skin of BALB/c pups. In 
both cases, skin was digested overnight at 4°C with 2 mg/ml Dispase  (Invitrogen) 
in PBS, pH 7.5, to remove the epidermis. Dermal cells were released 
from human tissue by scraping, passed through a 70-μm cell strainer (BD 
Biosciences), and expanded in 0.1% gelatine-coated fl  asks in complete me-
dium (EGM-2 MV; Cambrex Bio Science) at 37°C/5% CO2 in a humidi-
fi  ed atmosphere. Dermal cells were released from mouse skin by digestion 
for 30 min at 37°C with a mixture of 2 mg/ml collagenase A, 0.2 mg/ml 
ovine testicular hyaluronidase, 0.05 mg/ml DNase I, and 0.05 mg/ml 
elastase (all obtained from Roche). Digests were fi  ltered through a 70-μm 
cell strainer, and cells were cultured overnight in complete EGM-2 MV 
  medium. HDLECs and MDLECs were lifted with Accutase (PAA Laboratories) 
and immunoselected with mouse anti–human LYVE-1 mAb and rat anti–
mouse LYVE-1 mAb, respectively, followed by magnetic retrieval with the 
appropriate MACS bead preparations (Miltenyi Biotec). The resulting cells 
were cultured in EGM-2 MV using plastic tissue culture fl  asks that had been 
precoated with 0.1% gelatin (Invitrogen). All experiments were performed 
on confl  uent cells.
Cytokines and chemokines. Recombinant cytokines and chemokines 
(R&D Systems) were used at the following concentrations: IL-1α, 1 ng/ml; 
IL-2, 2 ng/ml; IL-6, 20 ng/ml; IL-8, 50 ng/ml; TNF-α, 0.1–10 ng/ml (see 
Results); TNF-β, 100 ng/ml; IFN-γ, 100 ng/ml; and MIP3-α, 100 ng/ml. 
Recombinant mouse TNF-α was used at 100 ng/ml.
Antibodies. mAb to soluble mouse LYVE–1 Fc (25) was generated in the 
rat, and polyclonal antisera to mouse or human LYVE-1 were generated 
and used as described previously after purifi  cation of Ig using Protein A/G–
Sepharose (25, 61). Other antibodies were rat anti–mouse CD31 (Cymbus 
Biotechnology); goat anti–mouse ICAM-1, SLC, and JE (R&D Systems); 
mouse anti–human ICAM-1 and ICAM-2 (Serotec); mouse anti–human 
E-selectin (R&D Systems); and mouse anti–human VCAM-1, CD31, 
and CD34 (BD Biosciences). Rabbit anti–human Prox-1 and anti–human 
podoplanin were purchased from Fitzgerald Industries International, Inc. 
Specifi  city of rabbit antisera was confi  rmed using podoplanin Fc. Hamster 
anti–mouse podoplanin (clone 8.1.1) was from the Developmental Studies 
Hybridoma Bank (University of Iowa, Iowa City, IA). Rabbit polyclonal 
sera against mouse and human podoplanin were donated by D. Kerjaschki 
(Medical University of Vienna, Vienna, Austria). Function-blocking 
mAbs P2A4 and P8B1 (anti–ICAM-1 and anti–VCAM-1, respectively) 
(62) were from the Developmental Studies Hybridoma Bank; 51-10C9 
(anti–VCAM-1) was from BD Biosciences; and both 15.2 (anti–ICAM-1) 
and 24 (anti–LFA-1) were gifts from N. Hogg (Cancer Research UK 
  London Research Institute, London, United Kingdom). Rat anti–mouse 
function-blocking mAbs against VCAM-1 (clone 6C7.1) (48) and ICAM-1 
(YN1/1.7.4) (47) were gifts from D. Vestweber (University of Münster, 
Münster, Germany). Isotype-matched antibodies (mouse, rat, rabbit, and 
goat IgG) were purchased from Sigma-Aldrich. All other primary anti-
bodies were obtained from Cancer Research UK. Secondary antibody Alexa 
Fluor 488 (green) or Alexa Fluor 568/594 (red) conjugates were obtained 
from Invitrogen.
Flow cytometry. Cells were lifted with Accutase (PAA Laboratories), sus-
pended in incubation buff  er (PBS–5% FCS, 0.1% azide) and incubated for 
30 min at 5°C with primary antibody, followed by washing and reincubation 
for 30 min at 5°C with the appropriate Alexa Fluor 488 goat conjugate be-
fore analysis on a fl  ow cytometer (FACSCalibur; BD Biosciences) using 
CellQuest software.
Immunofl  uorescent antibody staining of cells and tissues. For   single/
double immunofl  uorescent staining of cultured HDLECs and MDLECs in 
plastic dishes, appropriate primary antibodies were applied in PBS–5% FCS, 
and cells were incubated at 25°C for 30 min, followed by washing and rein-
cubating with Alexa Fluor secondary antibodies in PBS–5% FCS. Samples 
were fi  xed in 2% formaldehyde-PBS (vol/vol) for 10 min and mounted in 
Vectashield-DAPI (Vector Laboratories) before viewing under a fl  uores-
cence microscope (Axiovert; Carl Zeiss MicroImaging, Inc.).
For whole-mount staining, tissues were fi  xed overnight at 5°C in para-
formaldehyde (4% wt/vol in PBS, pH 7.4), blocked in PBS–Triton X-100 
(0.3% vol/vol supplemented with dried milk, 3% wt/vol), and incubated 
with the appropriate primary antibodies overnight at 5°C and fl  uorescent-
conjugated secondary antibodies for 2 h at 25°C before mounting in Vecta-
shield and viewing on a confocal microscope (Radiance 2000; Bio-Rad 
Laboratories) with sequential scanning.
For preparation of thin frozen sections, tissues were frozen in OCT 
Embedding Medium (purchased from R.A Lamb Laboratory Supplies) be-
fore cutting 8-μm or thinner sections by cryostat. Primary antibodies were 
applied, followed by Alexa Fluor conjugates. Sections were mounted in 
Vectashield, and images captured using a confocal microscope with sequen-
tial scanning.
To visualize DC migration across HDLEC monolayers, primary 
HDLECs were seeded onto the underside of gelatin-coated clear cell culture 
inserts (3-μm pore size; BD Biosciences), as described for a transmigration 
assay (see MDDC-HDLEC transmigration assay). CMFDA-labeled   MDDCs 
were applied, and after 10 h cells were fi  xed in paraformaldehyde and stained 
with rabbit antipodoplanin and mouse anti–VCAM-1 or anti–ICAM-1, and 
with goat anti–rabbit–conjugated Alexa Fluor 568 and goat anti–mouse Cy5 
(Chemicon). Images were captured using a confocal microscope with xy 
and xz scanning.
Endothelial cell proliferation assay. The proliferation rate of HDLECs 
was determined using a colorimetric assay that measured reduction of MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) to the 
  insoluble formazan product (63). In brief, 40 μl MTT solution (7.5 mg/ml in 
PBS, pH 7.5) was mixed with 200 μl culture medium and added to mono-
layers of endothelial cells cultured in 24-well dishes. After incubation for 1 h 
at 37°C, supernatants were discarded, and 200 μl of 0.04 M HCL in isopro-
panol was applied to the monolayer. Cell lysates were centrifuged for 4 min 
at 900 g, and the resulting supernatants were analyzed in a plate reader 
(model 680; Bio-Rad Laboratories) at 590 nm.
Chemokine ELISA. Supernatants from triplicate wells of confl  uent 
  primary HDLECs and MDLECs were assayed for the chemokines RAN-
TES, MCP-1 (JE), and MIP-3α using a commercial antigen capture ELISA 
method (Quantikine; R&D Systems), according to the manufacturer’s 
  instructions. In brief, appropriately diluted supernatants were   applied in tripli-
cate to precoated ELISA wells, alongside negative controls of medium alone 
and chemokine standards, applied in duplicate. Bound chemokines were 
detected using a secondary horseradish peroxidase–  conjugated antibody and 
substrate for measurement in a microplate reader at 490 nm.
Oxazolone-induced contact hypersensitivity. BALB/c male mice aged 
8–10 wk were sensitized by topical application of 3% (wt/vol) oxazolone 
(4-ethoxymethylene-2 phenyl-2-oxazoline-5-one; Sigma-Aldrich) in 95% 
aqueous. ethanol to the shaved abdomen (50 μl per mouse). The next day, 
a further 100 μl of 2.5% (wt/vol) oxazolone was applied to the same site. On 
day 5, the dorsal surface of the left ear was challenged in each case by topical 
application of 0.5% oxazolone solution (50 μl per ear), while the right ear 
(control) was treated with vehicle alone.
In vivo blockade of DC migration. BALB/c male mice aged 8–10 wk 
were sensitized by topical application of 3% (wt/vol) oxazolone in 95% 
aqueous ethanol to both ears (50 μl per ear). The next day, a further 50 μl 
of 3% (wt/vol) oxazolone was applied to the same site. On day 5, an JEM VOL. 203, November 27, 2006  2775
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intraperitoneal injection of 0.5mg of antibody in PBS—6C7.1 (anti–VCAM-1) 
(48), YN1/1.7.4 (anti–ICAM-1) (47), or rat IgG—was administered. On 
day 6, the shaved abdomen was challenged by topical application of 0.8% 
oxazolone solution and 1.5mg/ml FITC at 150 μl per animal. 24 h after 
challenge, mice were killed, and the axillary and inguinal lymph nodes were 
removed. Tissue was disrupted by 0.5 mg/ml collagenase D (Roche) for 30 
min at 37°C, passed through a 70-μm cell strainer (BD Biosciences), and 
stained with PE anti–mouse CD11c (BD Biosciences) for FACS analysis.
To observe blocking of DC migration from the dermis, contact hypersen-
sitivity was induced by oxazolone in BALB/c male mice by application to the 
abdomen. 5 d after sensitization, either YN1/1.7.4 (anti–ICAM-1) or 0.5 mg rat 
IgG was administered by intraperitoneal injection. 24h later, oxazolone was ap-
plied to both ears. 8 h after the challenge, 106 CMFDA-labeled bone marrow–
derived DCs per ear from a littermate (diff  erentiated in vitro in 20 ng/ml IL-4 
and GM-CSF) were dermally injected. 24 h later, animals were killed, and ear 
tissue was fi  xed in paraformaldehyde. Whole-mount staining was performed us-
ing hamster anti–mouse podoplanin with Alexa Fluor 568 and Cy5-conjugated 
goat anti–rat Cy5 to detect binding of neutralizing antibody within the tissue.
DNA microarray analyses. Total cellular RNA was isolated (RNeasy; 
QIAGEN) from freshly isolated primary HDLECs and MDLECs cultured 
for 24 h in EGM-2 MV medium alone or supplemented with 1 ng/ml TNF-α 
before synthesis and biotin labeling of cRNA probes and fragmentation 
  according to standard Aff  ymetrix protocols at the Cancer Research UK 
  Microarray Facility (Paterson Institute for Cancer Research, Manchester, 
UK). Probes were hybridized for 16 h to Aff  ymetrix GeneChip Human 
  Genome U133 Plus 2.0 or Mouse 430 arrays, as appropriate, and processed 
using a GeneChip Fluidics Station 450 according to recommended protocols 
(EukGE-WS2v5; Aff  ymetrix). Images were captured using the GeneChip 
Scanner 3000 (Aff  ymetrix). Transcript levels were determined using GeneChip 
Operating Software (GCOS1.2; Aff  ymetrix), and data were normalized by 
global scaling. Robust multi-array average (RMA) expression was measured 
by probe sequence information (GCRMA) in BioConductor R statistics and 
analyzed using Data Mining Tool (DMT 3.1; Aff  ymetrix) and GeneSpring 
7.2 (Silicon Genetics). Microarray data are available in the National Center 
for Biotechnology Information Gene Expression Omnibus (http://www.
ncbi.nlm.nih.gov/geo/) under accession no. GSE6257.
MDDCs. PBMCs were obtained from healthy donors, and monocytes were 
purifi  ed by positive selection using anti-CD14–conjugated magnetic micro-
beads (Miltenyi Biotec). MDDCs were generated by culturing monocytes 
for 5 d in RPMI–10% FCS supplemented with 50 ng/ml GM-CSF and 10 
ng/ml IL-4 (R&D Systems) and matured with LPS from 1μg/ml Salmonella 
abortus (Sigma-Aldrich). For fl  uorescent labeling, MDDCs were incubated 
with 2.5 μM Cell Tracker Green (Invitrogen) in EGM-2 MV media for 
40 min, then washed in media and rested for 30 min.
MDDC-HDLEC transmigration assay. Primary HDLECs were seeded 
onto the underside of gelatin-coated Fluoroblok cell culture inserts (3-μm 
pore size; BD Biosciences) and incubated for 2 h at 37°C before being placed 
into a companion plate (BD Biosciences) containing EGM-2 MV medium. 
Cells were cultured until confl  uent and stimulated with 1 ng/ml TNF-α 
(R&D Systems) 24 h before use. To assess the contribution of individual ad-
hesion molecules expressed in HDLECs, cells were incubated in the pres-
ence of blocking antibodies (see Antibodies) for 30 min before the addition 
of 0.5 × 106 fl  uorescently labeled MDDCs per well. To assess the contribu-
tion of ICAM-1 expressed on MDDCs, fl  uorescently labeled MDDCs were 
incubated at 37°C for 30 min in the presence of ICAM-1 blocking mAb 
15.2 or mouse IgG and washed three times in medium before applying to 
the HDLEC monolayer. Numbers of MDDCs transmigrating through the 
fi  lter and monolayer into the lower chamber were recorded at 30-min inter-
vals on an automated fl  uorescent multiprobe plate reader (Synergy HT; 
Bio-Tek) at 37°C using KC4 software (Biotech). The fl  uorescent signal was 
calibrated against a standard curve, and reverse transmigration was expressed 
as the number of DCs in the lower chamber.
To assess the permeability of the monolayer, 50 μg/ml Alexa Fluor 488 
fl  uorescent dye was applied to the upper compartment of the Fluoroblok cell 
culture inserts with confl  uent HDLECs on the underside. Fluorescence in 
the lower chamber was recorded at 30-min intervals at 37°C, calibrated 
against a standard curve, and expressed as the concentration of dye in the 
lower chamber.
MDDC-HDLEC adhesion assay. Primary HDLECs were seeded in gelatin-
coated 24-well dishes and cultured until confl  uent, then stimulated with 
1 ng/ml TNF-α. Where appropriate, HDLECs were incubated in the pres-
ence of blocking antibodies (see Antibodies) for 30 min before the addition 
of fl  uorescently labeled 0.5 × 106 MDDCs per well. Plates were incubated 
for either 3 or 10 h, medium was removed, and cells were washed with PBS 
to remove nonadherent MDDCs. Numbers of MDDCs adhering were mea-
sured by a fl  uorescent plate reader, and the fl  uorescent signal was calibrated 
against a standard curve of fl  uorescently labeled DCs.
Online supplemental material. Detailed characterization of the eff  ects of 
TNF-α on CAM expression by HDLECs and MDLECs (Figs. S1–S3), the 
association of DCs with ICAM-1–positive mouse lymphatics in vivo (Fig. 
S4), the phenotype of MDDCs (Fig. S5), and various features of the HDLEC 
in vitro transmigration assays (Figs. S6–S8) are available online. Tables S1 
and S2 show Aff  ymetrix GeneChip Human Genome U133 Plus 2.0 and 
Mouse 430 array data, respectively. Online supplemental material is available 
at http://www.jem.org/cgi/content/full/jem.20051759/DC1.
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